United States · Platforms & data · Stocktwits
Biotech Dealmaker: Early-Stage Platforms And Tools Draw Capital As Full Buyouts Remain On The Sidelines This Week
Detailed summary
Large drugmakers and specialized investors continued to favor targeted capability additions, asset purchases, and co-funding arrangements over outright buyouts of late-stage…
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (stocktwits.com)
